{"DataElement":{"publicId":"3212002","version":"1","preferredName":"Patient Endometrial Malignant Neoplasm Eligibility Determination Ind-3b","preferredDefinition":"the yes, no, or not applicable indicated related to criteria to determine eligibility of patients based on atypical neoplastic relating to or composed of endometrium.","longName":"3121654v1.0:2958018v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3121654","version":"1","preferredName":"Patient Endometrial Malignant Neoplasm Eligibility Determination","preferredDefinition":"information related to criteria to determine eligibility of patients based on atypical neoplastic relating to or composed of endometrium.","longName":"2233604v1.0:3121652v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3121652","version":"1","preferredName":"Endometrial Malignant Neoplasm Eligibility Determination","preferredDefinition":"Relating to or composed of endometrium.:A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.  Malignant neoplasms usually metastasize to distant anatomic sites and may recur after excision.  The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin's and non-Hodgkin's lymphomas, leukemias, melanomas, and sarcomas. -- 2004:Criteria to determine eligibility of patients for medical care programs and services.","longName":"C13322:C9305:C25171","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Endometrial","conceptCode":"C13322","definition":"Relating to or composed of endometrium.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Eligibility Determination","conceptCode":"C25171","definition":"The act of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8B5F9B83-A92E-BE32-E040-BB89AD431319","latestVersionIndicator":"Yes","beginDate":"2010-07-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-07-14","modifiedBy":"ONEDATA","dateModified":"2010-07-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8B5F9B83-A93F-BE32-E040-BB89AD431319","latestVersionIndicator":"Yes","beginDate":"2010-07-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-07-14","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506036","version":"1","preferredName":"Yes No Not Applicable Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no/not applicable.","longName":"YES_NO_NA_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"14","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Not Applicable","valueDescription":"Not Applicable","ValueMeaning":{"publicId":"3261243","version":"1","preferredName":"Not Applicable","longName":"3261243","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA2BBD66-6581-A6F2-E040-BB89AD4311D3","latestVersionIndicator":"Yes","beginDate":"2011-08-10","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-08-10","modifiedBy":"RAGUNATHANU","dateModified":"2024-02-05","changeDescription":"12/15/15 added N/A as alternate VM-tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-759A-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75A4-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-7590-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2694966","version":"1","preferredName":"Ind-3b","preferredDefinition":"A response or indicator that can have a value of yes, no, or not applicable.","longName":"C49797","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes, No, or Not Applicable Response","conceptCode":"C49797","definition":"A response or indicator that can have a value of yes, no, or not applicable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"3EBCA780-282F-4411-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-11-12","endDate":"2016-04-27","createdBy":"CURTIST","dateCreated":"2007-11-12","modifiedBy":"TAYLORT","dateModified":"2020-10-02","changeDescription":"10.2.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Retired DBW 04-27-2016 per Tina Taylor approved by Dianne Reves","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-757C-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ZHANGWE","dateModified":"2019-01-24","changeDescription":"3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. 8/3/2015 Corrections made to VD in order to restore to original format: removed C49486 as rep term and replaced with C49797; restored long name and definition per Dianne Reeves/tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"10000287","version":"1","longName":"GOG-0213","context":"NRG"},{"publicId":"4104909","version":"1","longName":"GOG-0213","context":"NRG"},{"publicId":"10000288","version":"1","longName":"GOG-0213","context":"NRG"},{"publicId":"4104903","version":"1","longName":"GOG-0170R","context":"NRG"},{"publicId":"10000427","version":"1","longName":"GOG-0170R","context":"NRG"},{"publicId":"10000426","version":"1","longName":"GOG-0170R","context":"NRG"},{"publicId":"10000078","version":"1","longName":"GOG-0186H","context":"NRG"},{"publicId":"10000077","version":"1","longName":"GOG-0186H","context":"NRG"},{"publicId":"4104904","version":"1","longName":"GOG-0186H","context":"NRG"},{"publicId":"10000501","version":"1","longName":"GOG-0170Q","context":"NRG"},{"publicId":"4104902","version":"1","longName":"GOG-0170Q","context":"NRG"},{"publicId":"10000502","version":"1","longName":"GOG-0170Q","context":"NRG"},{"publicId":"10000284","version":"1","longName":"GOG-0235","context":"NRG"},{"publicId":"10000285","version":"1","longName":"GOG-0235","context":"NRG"},{"publicId":"4104912","version":"1","longName":"GOG-0235","context":"NRG"},{"publicId":"10000693","version":"1","longName":"GOG-9923","context":"NRG"},{"publicId":"4104931","version":"1","longName":"GOG-9923","context":"NRG"},{"publicId":"10000692","version":"1","longName":"GOG-9923","context":"NRG"},{"publicId":"4104898","version":"1","longName":"GOG-0258","context":"NRG"},{"publicId":"4104917","version":"1","longName":"GOG-0262","context":"NRG"},{"publicId":"10000174","version":"1","longName":"GOG-0262","context":"NRG"},{"publicId":"10000175","version":"1","longName":"GOG-0262","context":"NRG"}]}],"AlternateNames":[{"name":"GOG","type":"USED_BY","context":"NRG"},{"name":"3121654v1.0:2958018v1.0","type":"USED_BY","context":"NRG"}],"ReferenceDocuments":[{"name":"If the patient has a synchron","type":"Preferred Question Text","description":"If the patient has a synchronous primary endometrial cancer or past history of endometrial cancer, is it more advanced than Stage I-B OR with greater than superficial myometrial invasion with vascular or lymphatic invasion OR poorly differentiated subtypes including papillary serous, clear cell or other FIGO Grade 3 lesions","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Does the patient have FIGO 2009 Surgical Stage I or II endometrial clear cell or serous carcinoma with positive peritoneal cytology?","url":null,"context":"CTEP"},{"name":"CRF Text2","type":"Alternate Question Text","description":"If yes, is the stage greater than IB OR is there more than superficial myometrial invasion without vascular or lymphatic invasion OR are there any poorly differentiated subtypes, including papillary serous, clear cell or other FIGO Grade 3 lesions?","url":null,"context":"CTEP"},{"name":"CRF Text3","type":"Alternate Question Text","description":"If the patient has a past history of primary endometrial cancer, is it more advanced than Stage I-B OR with myometrial invasion greater than superficial, with vascular or lymphatic invasion OR with a poorly differentiated subtype, including papillary serous, clear cell or other FIGO grade 3 lesions?","url":null,"context":"CTEP"},{"name":"CRF Text4","type":"Alternate Question Text","description":"If the patient has a history of primary endometrial cancer are the following conditions met: Stage not greater than I-B; no more than superficial myometrial invasion, without vascular or lymphatic invasion; no poorly differentiated subtypes, including papillary serious, clear cell or other FIGO Grade 3 lesions?","url":null,"context":"CTEP"},{"name":"GOG_CRF Text","type":"Alternate Question Text","description":"If yes, have all of the following conditions been met: Stage was not greater than 1B; there was no more than superficial myometrial invasion without vascular or lymphatic invasion; there were no poorly differentiated subtypes, including papillary serous, clear cell or other FIGO grade 3 lesions?","url":null,"context":"NRG"},{"name":"NRG_CRF Text","type":"Alternate Question Text","description":"If the patient has a synchronous primary endometrial or past history of primary endometrial cancer, is it more advanced than Stage I-B OR with invasion greater than superficial myometrial invasion, with vascular or lymphatic invasion OR with grade 3 histology (including poorly differentiated, papillary serous or clear cell components or other FIGO grade 3 lesions)?","url":null,"context":"NRG"},{"name":"CRF Text 5","type":"Alternate Question Text","description":"Does the patient have any non-endometrioid histology (such as serous, clear cell, or carcinosarcoma)?","url":null,"context":"CTEP"},{"name":"CRF Text 6","type":"Alternate Question Text","description":"Is the patient currently participating and receiving cancer-directed study therapy for endometrial cancer, or have they participated in a study of an investigational agent and received cancer-directed study therapy for endometrial cancer within 4 weeks prior to enrollment?","url":null,"context":"NRG"},{"name":"NRG_eCRF_Text","type":"Alternate Question Text","description":"Does the patient have non-recurrent, chemo-na√Øve, HER2 positive endometrial serous carcinoma or endometrial carcinosarcoma?","url":null,"context":"NRG"},{"name":"NRG_eCRF_Text1","type":"Alternate Question Text","description":"Does the patient have non-recurrent, chemo-naive, HER2 positive endometrial serous carcinoma or endometrial carcinosarcoma?","url":null,"context":"NRG"}],"origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9F9044F0-EAFD-EB9C-E040-BB89AD431ED8","latestVersionIndicator":"Yes","beginDate":"2011-03-28","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-03-28","modifiedBy":"TYRRELLM","dateModified":"2023-12-01","changeDescription":"Replaced VD Assessments Ind-3b 2958018v1 with VD ID#3506036 - Yes No Not Applicable Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}